The burgeoning hemp industry stands poised for explosive growth if the federal government undertakes the crucial step of rescheduling cannabis. Currently, its classification as a Schedule I drug creates monumental barriers to research, limits banking and investment options, and perpetuates unjust policies. Rescheduling could unlock a "Green Rush,"